| Expression pattern: |
UP |
| Associated gene: |
ZFX, Bcl-2, Bax, PCNA, Ago2 |
| Associated microRNA: |
miR-377-3p |
| Biological function: |
hsa_circ_0000567 promotes acquired gefitinib resistance, cell viability, colony formation, proliferation-associated protein expression, and tumor growth in gefitinib-resistant LUAD cells, while inhibiting apoptosis; its depletion suppresses these malignant and drug-resistant phenotypes. |
| Molecular mechanism: |
hsa_circ_0000567 functions as a ceRNA/miRNA sponge for miR-377-3p, thereby regulating the downstream target ZFX and modulating apoptosis- and proliferation-related proteins in gefitinib-resistant LUAD cells. |
| Biological pathway or process: |
ceRNA regulation (other); proliferation (promotes); apoptosis (inhibits); chemoresistance (promotes); drug resistance (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RNase R Treatment; RT-qPCR; Clinical Sample Validation; Transfection; MTT; Colony Formation Assay; Annexin V/PI Flow Cytometry; Western Blot; In Vivo Animal Model; Luciferase Reporter Assay; RIP (RNA Immunoprecipitation); Bioinformatics Analysis |
| Clinical significance: |
Higher hsa_circ_0000567 correlated with advanced tumor burden and was associated with larger tumor size and higher TNM stage; it was proposed as a potential biomarker and therapeutic target for gefitinib therapy resistance in NSCLC/LUAD. |
| Description: |
hsa_circ_0000567 is up-regulated in LUAD and further elevated in gefitinib-resistant LUAD tissues and cells. Its depletion suppresses gefitinib resistance, proliferation, colony formation, and xenograft tumor growth while promoting apoptosis, acting through a hsa_circ_0000567/miR-377-3p/ZFX ceRNA mechanism. Clinically, higher hsa_circ_0000567 is associated with advanced tumor burden, suggesting potential biomarker and therapeutic relevance in gefitinib-resistant LUAD. |
| Confidence score: |
0.7591 |